A patent review of anticancer CDK2 inhibitors (2017-present)
{{output}}
Introduction: The success of the CDK4/6 inhibitor Ibrance™ (Palbociclib) as an anticancer agent inspired and directed more efforts toward the discovery of selective cyclin-dependent kinase (CDKs) inhibitors. CDK2 is a member of ... ...
